Announcement of management change

We are pleased to inform you that Fumikazu Wanibuchi, President and CEO, has retired and Philip Davy, head of global business development and President & CEO of Braizon Therapeutics US ,Inc. has been appointed as President and CEO on Sep 29,2022.

We change our management in order to strengthen our business further so that we can quickly realize our vision of “becoming a leading company in drug delivery to the brain in central nervous system diseases”. We will continue to unite Braizon Team and devoted efforts for the development of our business, and please continue your support to us.